Deutsche Bank AG Increases Stock Holdings in LivaNova PLC $LIVN

Deutsche Bank AG increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 84.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 90,333 shares of the company’s stock after buying an additional 41,428 shares during the quarter. Deutsche Bank AG owned 0.17% of LivaNova worth $3,548,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in LivaNova by 13.5% during the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock worth $104,755,000 after buying an additional 316,993 shares during the last quarter. Capital Research Global Investors grew its stake in LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock worth $74,690,000 after buying an additional 258,730 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in LivaNova by 8.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock worth $60,710,000 after buying an additional 107,693 shares during the last quarter. Redmile Group LLC grew its stake in LivaNova by 19.3% during the 4th quarter. Redmile Group LLC now owns 1,043,539 shares of the company’s stock worth $48,326,000 after buying an additional 168,500 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in LivaNova by 0.6% during the 4th quarter. Nuveen Asset Management LLC now owns 823,412 shares of the company’s stock worth $38,132,000 after buying an additional 5,080 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Down 0.8%

LivaNova stock opened at $53.27 on Tuesday. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $57.35. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The company has a market cap of $2.91 billion, a PE ratio of -13.69 and a beta of 0.92. The business’s 50-day simple moving average is $45.84 and its two-hundred day simple moving average is $42.84.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%. The firm had revenue of $352.50 million for the quarter, compared to the consensus estimate of $332.20 million. During the same quarter in the prior year, the business earned $0.93 earnings per share. The company’s revenue was up 10.6% compared to the same quarter last year. Equities analysts anticipate that LivaNova PLC will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. Wolfe Research upgraded LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research note on Tuesday, May 20th. Robert W. Baird boosted their price target on LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. Finally, Barclays dropped their price target on LivaNova from $56.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 8th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, LivaNova presently has an average rating of “Buy” and an average target price of $59.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.